GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (CHIX:GMABc) » Definitions » ROC (Joel Greenblatt) %

Genmab AS (CHIX:GMABC) ROC (Joel Greenblatt) % : 416.94% (As of Dec. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Genmab AS ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Genmab AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 416.94%.

The historical rank and industry rank for Genmab AS's ROC (Joel Greenblatt) % or its related term are showing as below:

CHIX:GMABc' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 119.69   Med: 225.16   Max: 2780.55
Current: 243

During the past 13 years, Genmab AS's highest ROC (Joel Greenblatt) % was 2780.55%. The lowest was 119.69%. And the median was 225.16%.

CHIX:GMABc's ROC (Joel Greenblatt) % is ranked better than
96.93% of 1402 companies
in the Biotechnology industry
Industry Median: -310.545 vs CHIX:GMABc: 243.00

Genmab AS's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -0.70% per year.


Genmab AS ROC (Joel Greenblatt) % Historical Data

The historical data trend for Genmab AS's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS ROC (Joel Greenblatt) % Chart

Genmab AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 264.02 162.98 172.00 119.69 245.03

Genmab AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 95.79 167.51 220.33 185.23 416.94

Competitive Comparison of Genmab AS's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Genmab AS's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Genmab AS's ROC (Joel Greenblatt) % falls into.


';

Genmab AS ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6310 + 71 + 0) - (4455 + 39 + 0)
=1887

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6590 + 62 + 0) - (5192 + 24 + 0)
=1436

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Genmab AS for the quarter that ended in Dec. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=14624/( ( (1801 + max(1887, 0)) + (1891 + max(1436, 0)) )/ 2 )
=14624/( ( 3688 + 3327 )/ 2 )
=14624/3507.5
=416.94 %

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genmab AS  (CHIX:GMABc) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Genmab AS ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Genmab AS's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines